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Abstract
Opisthorchis viverrini is considered among the most important of the food-borne trematodes due to its strong association
with advanced periductal fibrosis and bile duct cancer (cholangiocarcinoma). We investigated the relationship between
plasma levels of Interleukin (IL)-6 and the risk of developing advanced fibrosis and bile duct cancer from chronic
Opisthorchis infection. We show that IL-6 circulates in plasma at concentrations 58 times higher in individuals with
advanced fibrosis than age, sex, and nearest-neighbor matched controls and 221 times higher in individuals with bile duct
cancer than controls. We also observed a dose-response relationship between increasing levels of plasma IL-6 and
increasing risk of advanced fibrosis and bile duct cancer; for example, in age and sex adjusted analyses, individuals with the
highest quartiles of plasma IL-6 had a 19 times greater risk of developing advanced periductal fibrosis and a 150 times
greater risk of developing of bile duct cancer than individuals with no detectable level of plasma IL-6. Finally, we show that a
single plasma IL-6 measurement has excellent positive predictive value for the detection of both advanced bile duct fibrosis
and bile duct cancer in regions with high O. viverrini transmission. These data support our hypothesis that common
mechanisms drive bile duct fibrosis and bile duct tumorogenesis from chronic O. viverrini infection. Our study also adds a
unique aspect to the literature on circulating levels of IL-6 as an immune marker of hepatobiliary pathology by showing that
high levels of circulating IL-6 in plasma are not related to infection with O. viverrini, but to the development of the advanced
and often lethal pathologies resulting from chronic O. viverrini infection.
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Introduction
Over 750 million people (10% of the human population) are at
risk of infection with a food-borne trematode, with more than 40
million people currently infected [1]. Opisthorchis viverrini is consid-
ered among the most important of the food-borne trematodes due
to its strong association with hepatobiliary pathologies that include
advanced bile duct fibrosis (periductal fibrosis or APF) [2–5] and
cholangiocarcinoma (CCA) [3,6–11]. In Thailand, an estimated 10
million people are infected with O. viverrini [12], where uncooked
cyprinoid fish (the intermediate host for the parasite) are a staple of
the diet [13]. While infection with O. viverrini can be eliminated by
chemotherapy (the anthelmintic praziquantel), culinary practices in
Thailand result in rapid and prolonged re-infection after treatment.
In the Northeastern region of Thailand (Isaan), individuals are often
infected with O. viverrini for a lifetime [7,14,15].
As shown in our community-based ultrasound studies along the
Chi River basin in Isaan (Khon Kaen, Thailand) [16,17],
important pathogenic changes occur early and asymptotically to
the bile duct during O. viverrini infection, including fibrosis in the
intrahepatic bile duct (periductal fibrosis). As with other forms of
hepatic fibrosis, periductal fibrosis from chronic opisthorchiasis is
probably the result of repeated injury sustained by the biliary
epithelium from a combination of the mechanical, toxic, and
immune mechanisms of the fluke in the bile duct [for review see
[18]]. As individuals are infected with O. viverrini for many years
(often a lifetime), a persistent cycle of tissue damage and repair
takes place in the intrahepatic biliary ducts, creating a chronic
inflammatory milieu that stimulates periductal fibrogenesis [for
review of this process see [18,19]]. In both the animal and human
models of chronic O. viverrini infection, this fibrotic deposition
along the biliary epithelium is a precursor event to CCA. For
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example, during the final phase of O. viverrini infection in the
hamster model (at 12 weeks after infection), the inflamed biliary
epithelium manifests fibrosis throughout its length, which is
followed rapidly by tumorogenesis [20,21]. In human autopsy
studies, extensive fibrotic deposition in the intrahepatic bile duct
routinely accompanies CCA tumors [10,22,23]. Although the
exact mechanism has yet to be determined, advanced fibrotic
lesions may precede tumorogenesis in the bile duct by producing a
‘‘smoldering and chronic inflammatory milieu’’ [24,25]. A key
factor in the maintenance of this chronic inflammatory milieu is
the production of soluble growth factors such as the cytokine IL-6
[24,25]. Studies of other hepatic pathogens also strongly implicate
IL-6 in progressive pathogenic fibrosis and carcinogenesis,
including hepatocellular fibrosis and hepatocellular carcinoma
(HCC) from Hepatitis B (HBV) and Hepatitis C Virus (HCV)
infection [26,27].
Due to its role in systemic inflammation, IL-6 is readily detected
in plasma [28]. As such, we sought to determine if the
concentration of IL-6 in the plasma of O. viverrini infected
individuals with APF and CCA was higher than age, sex, and
nearest-neighbor matched controls infected with O. viverrini but
without these advanced pathologies. We also sought to determine
the sensitivity and specificity of a single measurement of plasma
IL-6 to detect APF or CCA in these same individuals. Given the
poor prognosis associated with CCA, especially in resource-poor
settings such as Thailand, an early marker for the risk of the
hepatobiliary pathologies related to O. viverrini infection is urgently
needed.
Materials and Methods
Study design and setting
The current study presents baseline data collected from a
community–based cohort study of the risk factors associated with
the development of Advanced Periductal Fibrosis (APF) from
chronic opisthorchiasis (Table 1). A detailed description of this
population and the methods can be found in [17]. Individuals
from seven villages with high O. viverrini transmission, including
Nongnangkwan, Nongmuang, Loopka, Nongkham, Nongno,
Lawa and Chikokor in the vicinity of Khon Kaen (Thailand)
were surveyed. From this group of O. viverrini-infected individuals,
184 males and 236 females between the ages of 20 and 60 years
(inclusive) were enrolled into the study as ‘‘cases’’ or age, sex, and
nearest neighbor matched ‘‘controls’’. Individuals were enrolled as
‘‘cases’’ on the basis of an ultrasound (US) in which APF was
determined [17]. Individuals who were positive for O. viverrini but
negative for APF by US were defined as ‘‘controls’’ and matched
with cases by age (ten year age intervals), sex, and residence in the
same village (nearest-neighbor method). A positive pregnancy test
excluded female volunteers from participation in the ultrasonog-
Author Summary
O. viverrini is among the few parasites considered a Class 1
carcinogen because of its strong association with bile duct
cancer (cholangiocarcinoma). Currently, more than 40
million people are infected with O. viverrini worldwide.
Thailand has the highest prevalence of O. viverrini at 10
million people infected and also the highest incidence of
Opisthorchis-associated bile duct cancer (cholangiocarci-
noma) in the world. In the current study, we also show that
levels of IL-6 in plasma are associated in a dose-dependent
fashion with Opisthorchis-induced bile duct fibrosis
(periductal fibrosis) and cholangiocarcinoma. More impor-
tantly, we show that O. viverrini infection alone does not
elevate IL-6 levels in the plasma. It is only in the presence
of these advanced pathologies (advanced fibrosis or
cholangiocarcinoma) from chronic O. viverrini infection
that significantly elevates plasma levels of IL-6 are
observed. Moreover, we show that plasma IL-6 is an easily
accessible biomarker for the detection of advanced
periductal fibrosis and cholangiocarcinoma, which would
be a critical advance for this region of Thailand and other
countries in Southeast Asia, where the prevalence of O.
viverrini infection can reach as high as 80% and the
incidence of bile duct cancer is the highest in the world.
Table 1. Descriptive statistics for cases and controls used in the current study.
Advanced Periductal Fibrosis
Characteristics
Non-endemic
Controls1
Negative
Controls2
Positive
Cases3
CCA
Cases4
N (%) N (%) N (%) N (%)
Total 21 210 210 121
Sex
Male 11 (52.4%) 92 (43.8%) 92 (43.8%) 83 (68.6%)
Female 10 (47.6%) 118 (56.2%) 118 (56.2%) 38 (31.4%)
Age (in years)
20–29 15 (71.4%) 6 (2.9%) 6 (2.9%) 0 (0.0%)
30–39 1 (4.8%) 40 (19.0%) 39 (18.6%) 6 (7.2%)
40–49 3 (14.3%) 86 (41.0%) 87 (41.4%) 20 (24.1%)
50+ 2 (9.5%) 78 (37.1%) 78 (37.1%) 57 (68.7%)
1Non-endemic control’’ refers to age-matched Thai individuals who have never resided in an area with O. viverrini transmission.
2A control refers to an O. viverrini-infected individual who is age, sex, and nearest neighbor matched to a ‘‘case’’ but are negative for Advanced Periductal Fibrosis.
3A case refers to O. viverrini infected individual who is positive for Advanced Periductal Fibrosis.
4A case in this column refers to an individual with histologically proven O. viverrini associated cholangiocarcinoma (CCA) from the biological repository of the Liver Fluke
and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Thailand.
doi:10.1371/journal.pntd.0001654.t001
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raphy and blood draw. As such, 210 individuals were identified as
cases and matched 210 individuals as controls. Both cases and
control were asked to provide 30 ml of blood for baseline
immunology and hematological parameters. Individuals positive
for O. viverrini were referred to the local public health outpost for
treatment with praziquantel.
All subjects provided written informed consent using Informed
Consents Forms approved by the Ethics Committee of Khon
Kaen University School of Medicine, Khon Kaen, Thailand
(reference number HE480528) and the Institutional Review Board
of the George Washington University School of Medicine,
Washington, D.C (GWUMC IRB# 020864).
CCA cases
Aliquots of plasma from 121 cases of histologically proven, O.
viverrini associated CCA cases were pulled from the biological
repository of the Liver Fluke and Cholangiocarcinoma Research
Center, Faculty of Medicine, Khon Kaen University, Thailand
(Table 1). Of these pulled samples, 83 were male and 38 were
female. All samples were from patients who had liver resection
surgery as a part of palliative care for O. viverrini-associated CCA at
the Khon Kaen University Srinagarind Hospital, Khon Kaen,
Thailand.
Ultrasonography
A detailed description of the ultrasonography methods used in
this study can be found in the following references [16,17]. Briefly,
a mobile, high-resolution ultrasound (US) machine (GE model
LOGIQ Book XP) was used. Hepatobiliary abnormalities
including portal vein radical echoes, echoes in liver parenchyma,
indistinct gallbladder wall, gallbladder size, sludge and suspected
CCA were graded and recorded as previously described [16,17].
Individuals were classified as ‘‘Non-Advanced Periductal Fibrosis’’
or ‘‘controls’’ if the US grade was 0 or 1, and ‘‘Advanced
Periductal Fibrosis’’ or ‘‘case’’ if the US grade was 2 or 3 as
described in detail in our previous study [16,17]. Individuals with
alcoholic liver disease, which is seen as fatty liver by US exam,
were excluded from the analysis component of the study. Also,
individuals with marked hepatic fibrosis not related to O. viverrini
infection (e.g., cirrhosis from HBV or HCV) were also excluded
from the analysis component study.
Fecal exams to determine O. viverrini infection status
Eggs/parasite identification and egg counts were performed by
certified medical technicians using light microscopy at 106 and
406 magnifications as described in detail in our previous study
[16].
Plasma handling
Of the approximately 30 ml of blood collected from partic-
ipants, 8 ml of blood were collected in heparinized tubes for the
measurement of plasma cytokines. Plasma aliquots were grouped
in case-control sets that were handled together throughout the
processing and biochemical analysis. After blood draw, plasma was
separated and immediately aliquoted into 500 microliter (mL)
cryogenic tubes and frozen at 280uC until use. Biochemical
analysis was done on all samples simultaneously, with the position
of plasma samples varying at random during the processing.
Plasma samples from CCA patients were taken at the time of liver
resection, separated and aliquoted as above, and then stored at
280uC until use. CCA plasma samples were also randomly
interspersed among the cases and control sample sets during
biochemical analysis. The 21 non-endemic O. viverrini negative
control plasma were handled as above and interspersed repeatedly
at random among the actual case-control samples during
biochemical analysis.
Exploratory plasma cytokine measurements
Cytokine levels in plasma were examined for IL-1b, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12p70, interferon (INF) c, tumor
necrosis factor (TNFa), and TNFb production. The quantification
of plasma cytokines was analyzed using commercial FlowCytomix
bead-based multiplexing assays kits (Beckman-Coulter). Values
were quantified from standard curves using human recombinant
cytokines. A quantile regression model was used to determine the
median along with 95% confidence intervals (95% CI) to estimate
the differences between cases and controls for plasma cytokine
levels. When the data suggested a significant difference between
cases and controls, such as the levels of plasma IL-6, the plasma
were analyzed again using a sandwich ELISA as described below.
IL-6 ELISA
IL-6 cytokine levels in the plasma were measured by sandwich
enzyme-linked immunoadsorbent assay (ELISA) using a DuoSet
(R & D systems, Inc) according to the manufacturer’s instruction.
The level of IL-6 was determined by interpolating the Optical
Density of sample duplicates into a 4-parameter logistic-log model
of a standard curve of recombinant human IL-6 run in serial
dilutions on each ELISA plate. The concentration of IL-6 level is
expressed as picograms per microliter.
Statistics for Odd Ratios by quartile of IL-6 plasma
concentration
The percent distribution of selected demographic characteristics
were calculated for the four study groups: (1) non-endemic
negative controls, (2) O. viverrini positive (OV+) and APF negative
(controls), (3) OV+ APF positive (APF cases), and (4) OV+ and
CCA+ (CCA cases). Box and whisker plots display the distribution
of plasma IL-6 according to these groups. Age and sex adjusted
Odds Ratios (OR) and 95% Confidence Intervals (CIs) for
quartiles of plasma IL-6 concentration and their association with
APF or CCA status were determined using age and sex adjusted
multiple logistic regression analyses. A chi-square test for trend was
also used to test the effect of increasing quartile level of plasma IL-
6 on increasing risk of APF or CCA. The significance level for all
tests was set at 0.05, with a Bonferroni correction for multiple
testing. All statistical tests were two-sided. All analyses were
performed using Stata version 10 (College Station, TX).
Statistics for clinical epidemiology of IL-6 plasma
concentration and APF and CCA
Receiver-operating-characteristic (ROC) curves were obtained
by plotting the sensitivity versus 1–specificity for the full range of
IL-6 cut-off points in picograms per milliliter (pg/mL) for both
cases and controls to estimate the cutoff value that had the highest
overall validity. ‘‘Sensitivity’’ was calculated as the number of
individuals positive for APF or CCA testing positive for plasma IL-
6 at various cutpoints (by pg/mL) divided by the total number of
cases. ‘‘Specificity’’ was calculated as the number of individuals
negative for APF and CCA (controls) testing negative for plasma
IL-6 at various cutpoints (by pg/mL) divided by the total number
of controls. The area under the ROC curve was calculated by
determining the probability of correctly identifying (accuracy) a
randomly selected participant as either a case (APF positive or
CCA positive) or a non-case (APF negative or CCA negative). The
45-degree line in each ROC curve graph subsumes an area equal
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to 0.5 (50%), which is equivalent to using a coin toss procedure to
classify participants as either cases or controls. Using the ROC
curves, an optimal cutpoint was determined for the concentration
of plasma IL-6 that maximized the sensitivity and specificity in
classifying an individual at APF+ or CCA+. Based on this cutoff-
point, the positive predictive value (PPV), and negative predictive
value (NPV) of plasma IL-6 concentration to detected APF+ or
CCA+ status were determined. All analyses were performed using
Stata version 10 (College Station, TX).
Results
Study participants
As part of the inclusion criteria of the study, both cases and
controls had to be positive for O. viverrini as determined by the
presence of at least a single parasite ovum in feces. The baseline
characteristics of the enrolled participants are shown in Table 1,
with 210 cases (O. viverrini+ and APF+) and 210 controls (O.
viverrini+ and APF2). The controls were matched with cases by age
(ten year age intervals), sex, infection (O. viverrini positive) and
nearest-neighbor status (same village). The study sample included
more females (56.2%) than males (43.8%) (P,0.001). The mean
ages for cases (46.6 years of age) and controls (46.6 years of age)
did not differ significantly (P = 0.999). No statistically significant
difference (P.0.811) was observed in the intensity of O. viverrini
infection between cases (median= 142 epg) and controls (medi-
an = 130 epg). As shown in Table 1, both case and control groups
had a similar distribution of individuals when age was stratified by
ten-year intervals.
Among the 121 CCA samples in this study (Table 1), 117
(96.7%) were hepatectomies and 4 (3.3%) were small biopsy
specimens. Of the 117 hepatectomies, 74 (63.2%) were of the
mass-forming type and 8 (6.8%), 21 (18%), and 14 (12%) were
periductal-infiltrating, invasive intraductal, and mixed types,
respectively. Histologically, there were 41 well-differentiated
(33.9%), 8 moderately differentiated (6.6%), 9 poorly differentiated
adenocarcinomas (7.4%), 61 papillary carcinomas (50.4%), and 2
adenosquamous carcinomas (1.6%) of the 121 CCA cases studied.
The concentration of plasma IL-6 is significantly elevated
in individuals with Opisthorchis-induced APF and
Opisthorchis-induced CCA
Of the 11 cytokines tested only levels of the inflammatory
cytokine IL-6 were significantly elevated in individuals with
advanced periductal fibrosis and CCA compared to controls.
The frequency distributions of plasma IL-6 concentration for all
groups are presented in Figure 1. The IL-6 concentrations in
plasma for both cases and controls ranged between ,0.01 pg/mL
(undetectable) and 538.6 pg/ml, with a much wider range in APF
cases (,0.01 to 538.6 pg/ml) and CCA cases (,0.01 to 536.2 pg/
ml) than APF- controls (,0.01 to 173.1 pg/ml). An even narrower
range of plasma IL-6 concentration was recorded for the non-
endemic controls (,0.01 to 91.4 pg/ml). These data indicate that
there is far wider variation for the concentration of plasma IL-6 in
the advanced forms of O. viverrini induced pathogenesis than in
individuals with O. viverrini infection but no O. viverrini associated
pathology. Moreover, the median levels of plasma IL-6 concen-
tration were 58 times higher in APF+ cases than in controls (58
versus 1 pg/ml; P,0.001) and 221 times higher in CCA cases
than in controls (221 versus 1 pg/ml; P,0.001). CCA cases also
had higher levels of plasma IL-6 than APF cases (221 versus
58 pg/ml; P,0.001). Non-endemic controls had significantly
lower (mostly undetectable or ,0.01 pg/mL) plasma IL-6
concentrations (P,0.0001).
Figure 1. Plasma IL-6 levels are significantly elevated in individuals with Opisthorchis-induced APF and Opisthorchis-induced CCA.
The distribution of plasma concentration of Interleukin (IL)-6) in picograms per milliliter is shown in boxplots by study group. The bottom and top of
each box represent the 25th and 75th percentile (the lower and upper quartiles, respectively) of IL-6 concentration in plasma per group. The band
near the middle of each box represents the median value of IL-6 concentration per group. The whiskers represent the minimum (bottom) and
maximum (top) of IL-6 concentration per group.
doi:10.1371/journal.pntd.0001654.g001
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Elevated levels of plasma IL-6 significantly increase the
risk of APF in a dose-dependent manner
Increasing plasma concentrations of IL-6 significantly increased
the risk of APF: for every 10 pg/ml increase of IL-6, there is an
increase in the risk of APF by 22% (OR=1.22; 95% CI 1.16 to
1.29, P,0.001) in a model adjusted for age and sex (data not
shown). As shown in Table 2, the risk of APF increased with
increasing quartile concentration of plasma IL-6: OR=1.00 for
Quartile 1 (reference quartile); OR=3.94 (95% CI 2.21 to 6.81)
for Quartile 2; OR=7.95 (95% CI 4.73 to 13.36, P=,0.001) for
Quartile 3; and OR=18.94 (95%CI 10.17 to 35.25, P =,0.001)
for Quartile 4. A strong and significant trend for increasing
quartile concentration of IL-6 and increasing risk of APF was
found compared to individuals with no detectable levels of plasma
IL-6 (P,0.001).
Elevated levels of plasma IL-6 significantly increase the
risk of developing CCA in a dose-dependent manner
Elevated plasma concentrations of IL-6 significantly increased the
risk of CCA: for every 10 pg/ml increase of plasma IL-6
concentration, there was a 26% (OR=1.26; 95% CI 1.19 to 1.34,
P,0.001) increase in the risk of CCA in amodel adjusted for age and
sex. Table 3 shows that the risk of CCA increased in the 3rd and 4th
highest quartile concentrations of plasma IL-6: OR=4.55 (95% CI
2.05 to 10.11, P=,0.001) for Quartile 3 and OR=149.11 (95% CI
40.42 to 550.15, P=,0.001) for Quartile 4. A strong and significant
Table 2. Odds Ratios for plasma IL-6 levels for O. viverrini infected individuals with and without Advanced Periductal Fibrosis.
Quartile IL-6 (range in pg/ml)
11 2 3 4 P for Trend
(,0.01) (0.01 to 21.62) (21.63 to 82.79) (82.80 to 358.63)
n 180 76 128 127
Crude P=,0.001
OR2 1.00 3.88 8.02 18.55
95% CI3 – 2.21–6.81 4.78–13.46 9.99–34.42
P – ,0.001 ,0.001 ,0.001
Adjusted4 NA5
OR 1.00 3.94 7.95 18.94
95% CI – 2.24–6.95 4.73–13.36 10.17–35.25
P – ,0.001 ,0.001 ,0.001
1Individuals with undetectable levels of plasma IL-6 concentration are used as the reference group in Quartile 1.
2Odds Ratio.
395% Confidence Interval.
4Models were adjusted for age and sex simultaneously.
5Not Available.
doi:10.1371/journal.pntd.0001654.t002
Table 3. Odds Ratios for plasma IL-6 levels for O. viverrini infected individuals with1 and without Cholangiocarcinoma (CCA)2.
Quartile IL-6 (range in pg/ml)
13 2 3 4 P for Trend
(,0.01) (0.01 to 21.62) (21.63 to 82.79) (82.80 to 358.64)
N 145 21 83 82
Crude
OR4 1.00 0.47 4.76 182.46 P=,0.001
95% CI5 – 0.06–3.75 2/33–9.73 58.01–573.96
P – 0.475 ,0.001 ,0.001
Adjusted6
OR 1.00 0.21 4.55 149.11 NA7
95% CI – 0.02–2.30 2.05–10.11 40.42–550.15
1Individual without CCA are the controls from the case-control study in Table 2, that is, O. viverrini infected individuals who are negative for Advanced Periductal Fibrosis
(APF) by ultrasound and were age, sex, and nearest-neighbor matched with APF positive individuals (see Table 1).
2CCA cases were from the biological repository of the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Thailand.
3Individuals with undetectable levels of plasma IL-6 concentration are used as the reference group in Quartile 1.
4Odds Ratio.
595% Confidence Interval.
6Models were adjusted for age and sex simultaneously.
7Not Available.
doi:10.1371/journal.pntd.0001654.t003
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trend (P,0.001) for increasing quartile concentration of IL-6 and
increasing risk of CCA was also found compared to individuals with
no detectable level of plasma IL-6 (,0.01 pg/mL). Note that the
term ‘‘control’’ refers to the age, sex, and nearest-neighbor matched
controls for APF group and not for the CCA group and that the
logistic model is adjusted for age and sex.
Plasma IL-6 concentrations can be used to detect
individuals with Opisthorchis-induced advanced
periductal fibrosis (APF)
Figure 2 shows the ROC curve obtained by plotting the True
Positive Probability (sensitivity) against the False Negative Probability
(1–specificity) for the entire range of IL-6 cut-off points to predict the
presence of APF. Using a cutoff of greater than 11 pg/mL of plasma
IL-6, the sensitivity for the detection of APF was 80% and the
specificity was 74% (Table 4). In addition, for the cutoff of greater
than 11 pg/mL of plasma IL-6, the area under the ROC curve,
which is an indication of the ‘‘accuracy’’ of the test or proportion of all
tests that have given the correct result, was 78% (95%CI 74% to
83%). Table 4 also shows the Positive Predictive Value (PPV) and
Negative Predictive Value (NPV) of 76% and 79%, respectively, for
the detection of APF using plasma IL-6 levels greater than 11 pg/mL.
Plasma IL-6 concentrations can be used to detect O.
viverrini infected individuals with cholangiocarcinoma
(CCA)
Figure 3 shows the ROC curve obtained by plotting the True
Positive Probability (sensitivity) against the False Negative
Probability (1–specificity) for the entire range of IL-6 cut-off
points to predict the presence of CCA. Using a cutoff of greater
than 64 pg/mL of plasma IL-6, the sensitivity for the detection of
CCA was 80% and the specificity was 90% (Table 4). In addition,
for the optimal cutoff of .64 pg/mL of plasma IL-6, the area
under the ROC curve, which is an indication of the ‘‘accuracy’’ of
the test, was 89% (95% CI= 85% to 93%). Table 4 also shows the
Positive Predictive Value (PPV) and Negative Predictive Value
(NPV) of 82% and 88%, respectively, for the detection of APF
using plasma IL-6 levels .64 pg/mL. Note that the term control
refers to the age, sex, and nearest neighbor-matched controls for
APF group and not for the CCA group.
Discussion
These data show that elevated plasma concentrations of IL-6
are associated with a marked and significant increase in the risk of
O. viverrini-associated APF and CCA. As shown in Tables 2 and 3,
increasing levels of plasma IL-6 associate with increasing risk of
these advanced pathologies in a dose-dependent manner: for
example, individuals with the highest quartiles of plasma IL-6
concentration had a 19 times greater risk of developing APF and a
150 times greater risk of developing CCA than individuals with
undetectable levels of plasma IL-6 (,0.01 g/mL). As the data
were collected by a cross-sectional study design, the complicity of
IL-6 in these pathogenic processes remains to be determined: that
is, elevated plasma concentrations of IL-6 may simply reflect the
presence of these hepatobiliary abnormalities or, as shown in a
number of other studies, elevated plasma concentrations of IL-6
Figure 2. Plasma IL-6 concentrations can be used to detect individuals with Opisthorchis-induced advanced periductal fibrosis. A
receiver-operating-characteristic (ROC) curve plots the True Positive Probability (sensitivity) against the False Negative Probability (1– specificity) for
the full range of IL-6 cut-off points for the detection of Opisthorchis-induced Advanced Periductal Fibrosis (APF) as determined by ultrasound. The
area under the ROC curve is interpreted as the probability of correctly identifying (accuracy) a randomly selected participant as either a case (APF
positive) or a non-case (APF negative). The 45-degree line in the graph subsumes an area equal to 0.50 (50%), which is equivalent to using a coin toss
procedure to classify participants as either cases or controls. As determined by this ROC curve, the optimal cutpoint is 11 pg/mL of plasma IL-6, which
refers to the concentration that maximizes the ‘‘sensitivity’’ and the ‘‘specificity’’ of classifying an individual at APF positive. Based on this cutoff point,
the Positive Predictive Value (PPV) and the Negative Predictive Value (NPV) of plasma IL-6 concentration to detect APF was also determined (see
Table 4). All analyses were performed using Stata version 10 (College Station, TX). The ROC was derived from 210 O. viverrini infected individuals with
Advanced Periductal Fibrosis as determined by ultrasound (gold standard) versus 210 age, sex, and nearest neighbor-matched controls (O. viverrini
infected but negative for APF.)
doi:10.1371/journal.pntd.0001654.g002
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may play a key role in these pathogenic processes by creating an
inflammatory milieu that favors fibrotic deposition and carcino-
genesis in the bile duct [for reviews see [28–30]]. Notably, our data
show that O. viverrini infection alone does not elevate IL-6 levels
circulating in the plasma: e.g., age and sex matched O. viverrini
infected individuals without APF or CCA had negligible levels of
IL-6 in their plasma. It is only in the presence of advanced
pathology from chronic opisthorchiasis that plasma concentrations
of IL-6 are significantly elevated.
This study also shows that plasma IL-6 concentration can be
used to detect the risk for the advanced pathologies associated with
O. viverrini infection, many of which are subclinical. Our data on
the predictive values of a single measurement of plasma IL-6 to
detect CCA closely resemble recent data from Cheon and co-
workers [31] as well as other studies that have also reported a high
sensitivity and specificity for IL-6 in serum for non-Opisthorchis-
associated CCA [see [32] for review]. Our study adds a unique
aspect to the literature on circulating levels of IL-6 as an immune
Table 4. The diagnostic utility of plasma Interleukin (IL)-6 levels for Opisthorchis-induced pathologies.
N Cut off Percent (%)
Case Con1 Tot .pg/mL Sen2 Spec3 Acc4 PPV5 NPV6
APF7 210 210 420 11 80 74 77 76 79
CCA8 121 210 331 64 80 90 86 82 88
1Age, sex, and nearest-neighbor matched individuals, who were positive for O. viverrini infection and negative for APF as determined by ultrasound (US) were included
in the analyses and shown as controls in Table 1.
2Sensitivity.
3Specificity.
4Accuracy of the test or the area under the Receiver-Operating Characteristic (ROC) curves in Figures 2 and 3.
5Positive Predictive Value.
6Negative Predictive Value.
7O. viverrini infected individuals with Advanced Periductal Fibrosis as determined by US and shown as cases in Table 1.
8Plasma samples from histologically confirmed Opisthorchis-induced cholangiocarcinoma from the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of
Medicine, Khon Kaen University, Thailand.
doi:10.1371/journal.pntd.0001654.t004
Figure 3. Plasma IL-6 concentrations can be used to detect O. viverrini infected individuals with cholangiocarcinoma (CCA). A
receiver-operating-characteristic (ROC) curve plots the True Positive Probability (sensitivity) against the False Negative Probability (1– specificity) for
the full range of IL-6 cut-off points for the determination of Opisthorchis-induced cholangiocarcinoma (CCA). The area under the ROC curve is
interpreted as the probability of correctly identifying (accuracy) a randomly selected participant as either a case (APF positive) or a non-case (APF
negative). The 45-degree line in the graph subsumes an area equal to 0.50 (50%), which is equivalent to using a coin toss procedure to classify
participants as either cases or controls. As determined by this ROC curve, the optimal cutpoint is 11 pg/mL of plasma IL-6, which refers to the
concentration that maximizes the ‘‘sensitivity’’ and the ‘‘specificity’’ of classifying an individual at APF positive. Based on this cutoff point, the Positive
Predictive Value (PPV) and the Negative Predictive Value (NPV) of plasma IL-6 concentration to detect APF was also determined (see Table 4). All
analyses were performed using Stata version 10 (College Station, TX). The ROC was derived from 121 cases of histologically proven, O. viverrini
associated CCA cases from the biological repository of the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen
University, Thailand and 210 individuals who are O. viverrini infected but negative for APF and CCA.
doi:10.1371/journal.pntd.0001654.g003
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marker of hepatobiliary pathology by showing that high levels of
circulating IL-6 in plasma are not related to infection with O.
viverrini, but to the development of the advanced and often lethal
pathologies resulting from chronic O. viverrini infection: i.e., age
and sex matched controls with O. viverrini infection and no
pathology (APF- and CCA-) had undetectable levels of this
inflammatory cytokine in their plasma. Moreover, the ability of a
single IL-6 measurement to detect risk for O. viverrini associated
CCA and O. viverrini associated pathogenic fibrosis in the bile duct
(APF) is especially important in regions where O. viverrini is
endemic. In Isaan, Thailand, for example, the prevalence of O.
viverrini infection can reach as high as 79%; hence, an easily
accessible immune marker which can distinguish between
infection with O. viverrini and the advanced pathology induced by
this parasite would be particularly useful, where the incidence of
intraheptic CCA is among the highest in the world [33].
Currently, Thai individuals in O. viverrini endemic areas are
diagnosed only in the most advanced stages of CCA, when
treatment is essentially palliative. An easily measurable biomarker
for a precursor stage to CCA such as APF would be of great public
health importance by identifying those at greatest risk of CCA.
IL-6 is produced by numerous cell types, with a broad range of
effects, including the promotion of the innate immune response to
pathogens as well as the subsequent chronic inflammatory
reactions [28,30,34]. Once known as ‘‘hepatocyte-stimulating
factor’’ (HSF), IL-6 has been shown to play a key role in chronic
inflammatory conditions of the liver that lead to fibrotic lesions,
e.g., chronic alcohol consumption or viral hepatitis [26,35]. Our
previous studies have shown that crude antigens extracts antigens
from this parasite stimulate host PBMC from O. viverrini infected
individuals to produce high levels of IL-6 [16]. Our new data
indicate that elevated levels of IL-6 are not confined to the
immune response to parasite antigens, but circulate at elevated
levels in the plasma of individuals with advanced pathologies
associated with chronic O. viverrini infection, a role consistent with
the reputation of IL-6 as a key player in systemic inflammation.
We speculate that elevated concentrations of IL-6 circulating in
the plasma reflect the constant tissue repair response of the biliary
epithelia to the chronic mechanical, toxic, and immune injury
induced by the fluke [18]. When these tissue repair mechanisms
are activated transiently, the normal hepatobiliary structure and
function rapidly recovers: i.e., cholangiocytes would regenerate
and replace the necrotic or apoptotic cells, a process associated
with a local and transitory IL-6 response. However, as with
chronic alcohol consumption or infection with either HBC or
HCV infection, chronic opisthorchiasis creates a persistent
inflammatory milieu that stimulates fibrotic deposition
[25,29,36], a process that could be reflected or even partially
induced by the elevated concentrations of IL-6 circulating in the
plasma.
As with other inflammation associated hepatic pathologies
[25,29,36,37], tumors in the biliary tract may have activated the
wound-healing programs of the host chronically infected with O.
viverrini in an exaggerated and prolonged manner. A parallel
scenario is the presence of pathogenic fibrosis before the
development of HCC in patients with chronic HCV [for review
see [27]]. In the case of HCC, it is hypothesized that the
development of fibrosis and/or cirrhosis, plus a microenvironment
conducive to genomic instability, promotes neoplastic transforma-
tion in areas of hepatic fibrosis. Prominent among these processes
is the production of soluble growth factors such as IL-6 [25,29,36].
In the hamster animal model of O. viverrini-induced CCA, the
constant injury to bile duct epithelium by the liver fluke engages a
similar process [11]. During the early stage of infection (4 weeks),
fluke injury to the biliary epithelium results in inflammatory cell
infiltration, hyperplasia, and in the adenomatous change in the
bile duct epithelium. By the chronic stage of the infection (12
weeks), the immune response has transformed into prolonged
inflammation with fibrotic deposition along the bile duct wall and
ultimately CCA [18,38–41]. In autopsy studies [22,23] and studies
on liver tissue resected from Opisthorchis-induced CCA patients
for palliative care [5,18], fibrosis is routinely detected proximal to
neoplastic bile duct tissue.
In summary, this study identifies a significant relationship
between plasma IL-6 concentration and the advanced pathologies
associated with chronic O. viverrini infection. While in other settings
(e.g. Western countries) the causative agent of CCA remains
obscure, the single most important risk factor for intrahepatic
CCA in Thailand has long been established–infection with the
liver fluke O. viverrini [9]. As such, an easily accessible biomarker
such as plasma IL-6 would have great utility in predicting those at
risk (APF) or already with early CCA in a setting, where half of the
population are routinely exposed to this class I carcinogen O.
viverrini through the daily consumption of raw fish [42].
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